

F1
36. (Amended) The expression vector as set forth in claim 35, in which the mRNA-destablizing sequence is an mRNA-destablizing sequence of a c-fos gene.

F2
38. (Amended) Cells into which the expression vector as set forth in claim 35 has been transferred and selected with the drug.

39. (Amended) A process for producing cells expressing a gene product encoded by the expression vector as set forth in claim 35, comprising:

- (a) transferring the expression vector into cells,
 - (b) selecting cells which express the drug resistance gene from the transferred expression vector, and
 - (c) expressing the gene product encoded by the expression vector in the selected cells.
-

Kindly enter the following new claims.

F3
40. (New) A process for expressing a gene product encoded by the expression vector as set forth in claim 35, comprising:

- (a) transferring the expression vector into cells having gag and pol genes of a retrovirus,
- (b) selecting prepackaging cells which express the drug resistance gene from the transferred expression vector, and
- (c) expressing the gene product encoded by the expression vector in the selected prepackaging cells.

41. (New) The expression vector as set forth in claim 34, in which the mRNA-destablizing sequence is an mRNA-destablizing sequence of a c-fos gene.

42. (New) The expression vector as set forth in claim 34, in which the drug-resistance gene is selected from the group consisting of a neomycin resistance gene, a puromycin resistance gene and a hygromycin resistance gene.

43. (New) Cells into which the expression vector as set forth in claim 34 has been transferred and selected with the drug.

44. (New) A process for producing cells expressing a gene product encoded by the expression vector as set forth in claim 34, comprising:

- F3 conc*
- (a) transferring the expression vector into cells,
 - (b) selecting cells which express the drug resistance gene from the transferred expression vector, and
 - (c) expressing the gene product encoded by the expression vector in the selected cells.

45. (New) A process for expressing a gene product encoded by the expression vector as set forth in claim 34, comprising:

- (a) transferring the expression vector into cells having gag and pol genes of a retrovirus,
 - (b) selecting prepackaging cells which express the drug resistance gene from the transferred expression vector, and
 - (c) expressing the gene product encoded by the expression vector in the selected prepackaging cells.
-